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Introduction: Cognitive impairment has been observed in thalassemia patients (1) and it may be related to iron overload. Increased iron deposition was also reported in 
the basal ganglion regions in thalassemic patients previously. SWI with phase map allows more sensitive detection of iron content in the brain with higher image 
resolution (2). Therefore, we used SWI to quantify iron store in the brain of thalassemia patients with comparison to age matched normal subjects. 
Method: Thirty-four (17 Male) beta-thalassemia major patients and 34 (17 Male) age matched 
healthy normal volunteers were recruited for the study. The mean/SD of age was 24.4/6.1 and 
26.4/4.0 years for the patient and the control groups respectively.  MRI scan was performed using a 
Philips 3T scanner, and included a 3D gradient-echo sequence for SWI (FOV=230mm, 
Matrix=256x256, Slice thickness = 2mm, TR/TE =16/23ms) and a structural imaging sequence 
using either MPRAGE or 2D T1 weighted (T1W) technique for anatomical identification and 
image normalization. The phase image of the SWI sequence was processed to remove background 
field variation using a standard complex division method (3). All images were normalized to a 
standard brain template in SPM using the T1W image as a medium, and the mean phase image was 
created. Region-Of-Interests (ROI) were drawn on the mean phase map and included bilateral 
caudate nucleus (CN), putamen (PT), globus pallidus (GP), red nucleus (RN), substantia nigra (SN) 
and dentate nucleus (DN) (Fig 1). The mean phase value (PV) was calculated as the mean value of 
all non-positive voxels within a ROI as defined above; the restriction to non-positive voxels was 
imposed to alleviate the dipole effects which induce large positive phase value around regions of 
high susceptibility (e.g. caused by high iron density). Lower PV suggests higher iron loading. The left and right phase values were then averaged for further statistical 
analysis. We established normal range of PV by performing linear regression on the PV for each ROI with gender and age as independent variables in the control group. 
The expected normal PV for an individual can then be calculated as expectedPV = intercept + gender effect + age * (slope for age effect). The age and gender corrected 
PV (cPV) was then calculated as cPV = PV- expectedPV.  A PV 2.5 times standard deviation (SD) lower than the expected normal PV (i.e. cPV < -2.5*SD) was 
defined as Low Phase Value (LPV), which suggests iron over-loading; conversely a PV 2.5 times SD higher than the expected normal PV (i.e. cPV > 2.5*SD) was 
defined as High Phase Value (HPV), which suggests iron under-loading. Pearson’s correlation was performed between PV of each ROI with blood ferritin level taken 
within 2 months before and after the MR scan as well as its average over one year period. ANOVA analysis was performed to compare cPV of each ROI between 
patients receiving different types of chelation therapy, cPV rather than PV was used in order to control for the confounding effects of potentially different age of 
subjects receiving different types of chelation therapy.  
Results: Qualitatively, SWI was able to show nicely regions of high iron deposition. In some thalassemia cases, high amount of 
iron deposition was shown as low signal intensity in magnitude image and phase image in regions including the PT and the GP 
(Fig. 2). With increasing age, PV decreased in the control group in the PT, CN, DN, SN and RN, and the effect reached 
statistical significance for RN (p =0.016), which is in keeping with the literature of increased iron deposition with older age.  
Different patterns of iron loading was observed (Table 1).Out of 34 subjects, 10 had normal PV in all ROIs while 24 had 
abnormal PV in at least one of the ROIs. Among them, 5 (3 female) patients were categorized as “pure” iron over-loaded as at 
least one of the ROIs had LPV (Lower Phase Value, see Methods section for definition) while no ROI had HPV (High Phase 
Value, see Methods section for definition), of whom 1 involved PT, 2 GP, 1 CN and 4 RN; 17 (9 female) patients were 
categorized as “pure” iron under-loaded as at least one of the ROIs had HPV while none had LPV, of whom 11 involved GP, 8 
CN, 4 DN and 5 SN; 2 subjects (both male) had “mixed” findings, one had LPV in GP and HPV in CN, SN and RN, while the 
other had LPV in DN and HPV in CN. 
There was no significant correlation between measures of blood ferritin level and PV of the ROIs.   
For iron chelation therapy, 9 received DFO, 7 L1, 14 DFO& L1, and 4 Exjade. ANOVA analysis showed significant difference 
in cPV between patients with different chelation therapy in CN (p = 0.015) (Fig. 3) and SN (p = 0.036), while there was a trend 
towards statistical significance for PT (p = 0.075). Post-hoc analysis showed that cPV in CN was significantly higher for L1 
compared to DFO (p = 0.02) and Exjade (p = 0.045). Post-hoc analysis also showed significantly higher cPV in SN in patients 
receiving L1 compared to DFO (p=0.036). Quantitatively, cPV was found to be consistently higher in all other ROIs in patients 
receiving L1 compared to DFO, suggest L1 being a more effective iron chelation agent.  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion: SWI is sensitive to iron deposition in the brain, which, on the one hand, is nicely visualized as dark areas in magnitude image, and on the other hand, can 
be quantified using the phase map. Variations in the phase value most likely reflect differences in iron concentration (2). The wide range of phase value among 
thalassemia suggests that SWI can sensitively capture changes in iron concentration. We found not only patients with high iron loading but also patients with low iron 
loading. This variation is likely due to the dynamic interactions between the effects of regular blood transfusion and iron chelation therapy. Indeed, we found significant 
differences in phase value between patients with different iron chelation therapy, prompting further research on the best chelation therapy for a given individual. While 
over-loading of iron content is generally recognized as neuro-toxic due to the oxidative effects, it is not clear of the effect of lower iron concentration at cellular level or 
the level of overall cognitive ability although there are evidences that iron is important for the proliferation of cells. In conclusion, SWI is sensitive in measuring iron 
concentration in the brain and provides a valuable tool for iron assessment both for clinical trials and for individual evaluation. 
References: 1. Monastero R, et al. Acta neurologica scandinavica.2000; 102:162-168. 2. OGG RJ, et al. Magn Reson Imaging.1999; 17:1141-1148. 3. Wang Y, et al. 
2000. J Magn Reson Imaging. 2000; 12:661–670 
 Total # /Female # PT GP CN DN SN RN 
Normal 10/5       
Pure overload 5/3 1 2 1 0 0 4 
Pure underload 17/9 0 11 8 4 5 0 
Mixed 2/0 0 1+ 2- 1+ 1- 1- 
Fig. 1 shows placement of ROIs. 
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(ANOVA, p = 0.015) 
Fig. 2 shows an example of high iron 
concentration in PT and GP with low 
signal intensity in the phase map. 
Table 1 shows distribution of patients according their pattern of iron 
loading in the brain. (See main text for explanation).  
Fig. 3. Significant difference in
cPV was found in CN among
patients receiving different iron
chelation agents (p = 0.015).
Post-hoc analysis showed
significantly higher cPV in
patients receiving L1 compared
to DFO (p=0.02) and Exjade (p
= 0.045).
